Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize

• Published in: Nature communications Vol. 7; no. 1; p. 13019
• Main Authors: Adams, Stephen R., Yang, Howard C., Savariar, Elamprakash N., Aguilera, Joe, Crisp, Jessica L., Jones, Karra A., Whitney, Michael A., Lippman, Scott M., Cohen, Ezra E. W., Tsien, Roger Y., Advani, Sunil J.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 04.10.2016; Nature Publishing Group; Nature Portfolio
• Subjects: 13/1; 13/106; 13/31; 14/19; 14/34; 631/154/309/152; 631/67/1059/485; 64/60; 692/4028/67/1059/602; 82/51; Antibodies; Cancer therapies; Cell cycle; Chemotherapy; Clinical outcomes; Cytotoxicity; Drug dosages; Humanities and Social Sciences; multidisciplinary; Radiation therapy; Science; Science (multidisciplinary); Tumors; La Jolla California; United States > US; California
• ISSN: 2041-1723; 2041-1723
• DOI: 10.1038/ncomms13019

Tumour resistance to radiotherapy remains a barrier to improving cancer patient outcomes. To overcome radioresistance, certain drugs have been found to sensitize cells to ionizing radiation (IR). In theory, more potent radiosensitizing drugs should increase tumour kill and improve patient outcomes. In practice, clinical utility of potent radiosensitizing drugs is curtailed by off-target side effects. Here we report potent anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize to tumours based on surface receptor expression. While two classes of potent anti-tubulins, auristatins and maytansinoids, indiscriminately radiosensitize tumour cells, conjugating these potent anti-tubulins to anti-ErbB antibodies restrict their radiosensitizing capacity. Of translational significance, we report that a clinically used maytansinoid ADC, ado-trastuzumab emtansine (T-DM1), with IR prolongs tumour control in target expressing HER2+ tumours but not target negative tumours. In contrast to ErbB signal inhibition, our findings establish an alternative therapeutic paradigm for ErbB-based radiosensitization using antibodies to restrict radiosensitizer delivery. Drugs that sensitize tumour cells to ionizing radiation are prized because they can overcome resistance to radiotherapy. Here, the authors show that anti-tubulin drugs conjugated to cetuximab or trastuzumab can radiosensitize EGFR- or HER2-expressing tumors by increasing DNA damage and cell death due to ionizing radiation.